Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL

NCT01173679 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

10

Enrollment

OTHER

Sponsor class

Stopped Slow accrual

Conditions

Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions

DRUG: dasatinib
DRUG: Rituximab
DRUG: fludarabine

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]
[object Object]
[object Object]